NEW YORK (TheStreet) -- Shares of Teva Pharmaceuticals (TEVA) were falling 5.24 to $50.41 in late-afternoon trading on Wednesday after the U.S. Patent Office's Patent Trial and Appeal Board said that certain aspects of its multiple sclerosis drug Copaxone's patent are invalid.
Bernstein expects that the rest of the patents supporting Copaxone will ultimately be invalidated as well, according to CNBC.
Teva is an Israeli pharmaceutical company.
Separately, TheStreet Ratings team rates the stock as a "buy" with a ratings score of B.
Teva's strengths such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margin outweigh the fact that the company has had lackluster performance in the stock itself.
You can view the full analysis from the report here: TEVA
TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this article's author.